Wednesday, May 23, 2018
 
 
Company News: Page (1) of 1 - 05/16/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Bluebee Introduces BLUEBASE, a Streamlined Solution Transforming Data into Actionable Knowledge for Clinical and Translational Genomics Research
 
(May 16, 2018)

RIJSWIJK, Netherlands, May 16, 2018 /PRNewswire/ --

Bluebee Corporation announced today the release of BLUEBASE, a complete data management solution designed to transform next-generation sequencing (NGS) and metadata into actionable genomic knowledge with efficiency and clinical-grade security. BLUEBASE runs on the Bluebee core data analysis platform and provides post-sequencing intelligent data aggregation, ease of querying, and deep knowledge mining. BLUEBASE is aimed at diagnostic assay developers, pharmaceutical researchers, clinical trial operators, and investigators of population-scale initiatives, offering a turnkey solution to efficiently realize clinically-relevant information from large-scale genomic data.

     (Logo: http://mma.prnewswire.com/media/621211/Bluebee_Logo.jpg )



BLUEBASE aggregates, organizes, and stores combined genomic data sets, phenotypes, and other metadata from a vast ecosystem of curated public and private databases. With a customizable data model, BLUEBASE accommodates a wide scope of user-defined metadata and ontology frameworks, including the integration of a dynamic public knowledge base of 150 data sources and hundreds of millions of data records, comprised of publications, variant datasets, clinical studies, and other data sources. Private data sets and metadata are easily integrated within the system.

A range of applications are enabled by BLUEBASE, including discovery and validation of biomarkers, insight into patient stratification approaches, cross-study analyses by multi-disciplinary teams, identification of drug candidates for clinical trials and more. Having data mined and readily accessible in BLUEBASE within the Bluebee platform eliminates data redundancy and risks associated with physically transferring large, private datasets, further streamlining clinical genomics applications.

"BLUEBASE was created as part of our mission to further serve precision medicine initiatives," says Hans Cobben, CEO of Bluebee. "As part of the Bluebee platform, volume to value from genomic data is now achievable, with high efficiency and clinical-grade security."

About Bluebee  

Bluebee offers a secure global bio-informatics platform to process, analyze, share and store genomics data. Through a private cloud service, Bluebee supports users in clinical diagnostics, therapeutics and research with advanced analytics for genomic data driven medicine that will fuel the future of genomic discovery. Designed for cross-functional teams of clinicians and life science researchers the Bluebee platform effectively centralizes and manages genomics data processes and storage. Bluebee's multi-layered security is designed to meet both specific organizational and regulatory data protection requirements when analyzing and storing research or clinical grade data. Local data processing is guaranteed via "Data Residency Control" in state-of-the-art data centers. The service is available across all major European countries and US cities, as well as in Canada and Asia Pacific.

Find out more about Bluebee at www.bluebee.com

SOURCE Bluebee Corporation

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Science,Medical,Agricultural Science,Genetics,Science,Other,
Related Sites: AEC Newsroom ,   DMN Newswire ,   itbusinessnet.com ,   IBN - Internet ,   IBN - SoftwareDev ,   HTN - Health Technology Net
Related Newsletter: DMNForums ,   Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Bellevue Asset Management AG: Bellevue launches dedicated digital health fund
  • Interventional Cardiology Devices Market to be worth US$11.16 bn by 2022, Says TMR
  • Medical Fluid Bags Market will register 6.5% CAGR to cross USD 4.4 billion by 2024: Global Market Insights, Inc.
  • Longeveron Receives TEDCO Grant To Fund Stem Cell Research
  • Gross Revenue of Cancer Diagnostics Market will beat $156 Billion By 2024

    Cancer
  • Xulon Press Announces the Release of the Blessings of Mrs. Clare's Hair Gratitude, Forgiveness, Guidance and Nurturance in Caring for People Who Are Not Easy to Love
  • Moorestown Visiting Nurse Association joins the growing enTouch network in New Jersey
  • Achieve Life Sciences, Inc. Announces Reverse Stock Split
  • Accuray CyberKnife® Customer Achieves Top Score in Multiple Brain Metastases TROG 2018 Treatment Plan Study
  • Check-Cap Announces Publication of CE Mark Multicenter Clinical Study Results on C-Scan® in Gut
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines